Federal Actions on Drug Shortages: What the Government Is Doing in 2026

Walk into any hospital pharmacy today, and you might find a familiar frustration: the medicine your doctor prescribed isn't there. It’s not just an inconvenience; it’s a safety crisis. In late 2024, the United States faced a staggering number of active drug shortages, with reports varying between agencies but consistently pointing to a broken system. For patients, this means delayed treatments or risky substitutions. For healthcare providers, it means spending millions of dollars just trying to keep shelves stocked.

The federal government knows this is unsustainable. Over the last few years, Washington has shifted from merely tracking these shortages to actively intervening in the pharmaceutical supply chain. From new stockpiles of raw ingredients to AI-powered prediction tools, the strategy is evolving fast. But does it actually work? Let’s look at what the federal government is doing right now to fix the pipeline, where the money is going, and why some experts think we’re still missing the mark.

The New Strategy: Stockpiling Ingredients, Not Just Pills

For decades, the U.S. approach to medical emergencies focused on storing finished drugs-boxes of pills or vials ready to go. That model has changed dramatically with the introduction of the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), which is a federal stockpile of raw chemical components used to make essential medicines rather than the final packaged product. Originally piloted in 2020, SAPIR was significantly expanded by Executive Order 14178 in August 2025.

Why switch to raw materials? The math makes sense for emergency planners. Active pharmaceutical ingredients (APIs) are generally 40-60% cheaper to store than finished drugs. They also have a longer shelf life, often lasting three to five years more than their processed counterparts. More importantly, stockpiling APIs reduces immediate dependence on foreign suppliers. Currently, China supplies approximately 80% of the APIs for medications sold in the U.S., creating a massive single point of failure in our supply chain.

The reserve currently targets 26 essential medicines, including critical antibiotics, anesthetics, and oncology drugs. The Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR) identifies these based on national health security risks. HHS Secretary Robert F. Kennedy Jr. claimed in September 2025 that this reserve had already prevented 12 potential antibiotic shortages since its expansion. However, independent verification of these specific prevention claims remains difficult, highlighting a transparency gap in how success is measured.

How the FDA Tracks and Resolves Shortages

You can’t fix what you can’t see. The Food and Drug Administration (FDA) manages the FDA Drug Shortage Database, which is a publicly accessible online tool that lists active and resolved drug shortages to help healthcare providers plan for medication availability. As of November 2025, this database tracked over 1,200 active and resolved shortages. It serves as the central nervous system for shortage awareness, allowing hospitals to see what’s coming before it hits their doors.

The FDA doesn’t just list problems; it tries to solve them. According to agency data, they resolve about 85% of reported shortages through direct intervention. This usually involves regulatory flexibility, such as expediting inspections for manufacturing plants or granting temporary import authorizations from countries with different regulatory standards. A prime example was the saline shortage between 2018 and 2020, which affected 90% of U.S. hospitals. The FDA worked directly with manufacturers to clear bottlenecks, eventually restoring supply without needing a massive government bailout.

However, the system relies heavily on manufacturers reporting issues early. Federal law requires companies to notify the FDA six months in advance if they foresee a shortage. Compliance is spotty. Internal FDA data from August 2025 shows that only 58% of manufacturers meet this deadline. Small manufacturers, those with fewer than 50 employees, are particularly non-compliant, with an 82% failure rate to report on time. This lag means hospitals often get the news too late to adjust their purchasing strategies effectively.

Legislation and Funding: Who Pays for the Fix?

Policy changes require funding, and here the picture gets complicated. The 119th Congress is considering several bills aimed at strengthening the supply chain, most notably H.R.5316, known as the Drug Shortage Act. This bill aims to improve patient access to compounded medications during urgent shortages. The Congressional Budget Office estimated in October 2025 that this legislation would reduce shortages by 15-20% over five years, costing roughly $740 million. While that sounds significant, it represents less than 0.1% of total U.S. drug spending, leading critics to argue the financial incentive isn’t strong enough to change manufacturer behavior.

Budget cuts have also raised eyebrows. The 2026 HHS budget proposal includes $1.2 billion in cuts to FEMA’s emergency response capabilities and an 850-million-dollar reduction in state public health preparedness grants. Furthermore, funding for the Biomedical Advanced Research and Development Authority (BARDA), which previously funded innovations in continuous manufacturing, saw a 22% decrease from 2024 levels. Critics argue that while the administration talks up domestic production, it is simultaneously defunding the very programs that support advanced manufacturing research.

On the positive side, the Department of Commerce announced $285 million in CHIPS Act funding for pharmaceutical manufacturing facilities in September 2025. This marks the first major investment in domestic production capacity since 2022. However, industry analysts note this covers less than 5% of the estimated $6 billion needed to truly diversify API production away from overseas dependencies. It’s a start, but far from a complete solution.

The Human Cost: What Hospitals and Patients Are Facing

Behind every policy paper is a real-world impact on care. The American Hospital Association (AHA) reported that hospitals now spend an average of $1.2 million annually just managing drug shortages. That’s money taken away from patient care, staff training, or facility upgrades. More alarmingly, 68% of facilities reported treatment delays, and 42% reported medication errors directly linked to having to substitute drugs when the primary option was unavailable.

Pharmacists are on the front lines of this chaos. A 2025 survey by the American Society of Health-System Pharmacists found that 74% of pharmacists spend more than 10 hours per week sourcing alternative medications. On professional forums, pharmacists describe extreme scenarios, such as compounding chemotherapy drugs like cisplatin from raw materials because commercial supplies were exhausted. One pharmacist noted using five different manufacturers for the same drug within a single week, a practice that increases the risk of contamination and dosing errors.

Patients bear the brunt of these operational failures. A September 2025 report by Patients for Affordable Drugs found that 29% of Americans skipped doses due to unavailability-a distinct issue from skipping doses due to cost. Cancer patients are disproportionately affected, with 68% reporting treatment modifications due to shortages. When a drug isn’t available, doctors don’t just wait; they switch protocols, which can sometimes lead to less effective outcomes or increased side effects.

Technology and Future Predictions

Is technology the answer? The FDA launched its Enhanced Shortage Monitoring System in November 2025, integrating AI-powered predictive analytics. This system pulls from 17 different data streams, including shipping manifests, manufacturing batch records, and hospital purchasing patterns. Early results suggest it can forecast shortages with 82% accuracy up to 90 days in advance. If fully implemented, this could give hospitals the lead time they desperately need to secure alternatives.

However, technology alone can’t fix economic disincentives. The root cause of many shortages is simple economics: sterile injectables and generic antibiotics have thin profit margins. With just three companies controlling 68% of the sterile injectable market, there is little competition to drive innovation or redundancy. The FDA approved 56 new manufacturing facilities for critical drugs in 2024, but 42% were located outside the U.S., primarily in Ireland and Singapore. Reshoring production is slow and expensive, with new domestic API facilities requiring 28-36 months for FDA approval compared to 18-24 months in the EU.

Looking ahead, Goldman Sachs projects a 25% reduction in critical shortages by 2028 if all current initiatives are fully implemented. But the Congressional Research Service warns that without addressing the fundamental lack of profit in low-margin essential medicines, structural shortages will continue regardless of stockpiling efforts. The FDA’s recent announcement of expedited review pathways for second-source manufacturers offers a glimmer of hope, with 14 applications already in process that could add redundancy for eight critical drugs by mid-2026.

What You Can Do Right Now

If you’re a patient or caregiver, understanding the landscape helps you advocate for better care. Here are practical steps to navigate the current environment:

• Check the FDA Database: Before heading to the pharmacy, check the FDA Drug Shortage Database to see if your medication is listed. Knowing a shortage is active allows you to discuss alternatives with your doctor proactively.
• Ask About Generics and Therapeutic Alternatives: If your brand-name drug is short, ask if a generic equivalent is available. If not, ask if another drug in the same therapeutic class can achieve the same result. Always ensure this decision is made by your prescriber, not just the pharmacist.
• Build Relationships with Local Pharmacies: Independent pharmacies often have more flexibility to source hard-to-find drugs than large chains. Establishing a relationship with a local community pharmacist can provide earlier notice of shortages and faster access to alternatives.
• Report Issues: If you experience a shortage-related error or delay, report it. The FDA’s public portal has received thousands of reports, and this data helps prioritize which drugs need immediate regulatory attention.